Experienced in Catecholaminergic Polymorphic Ventricular Tachycardia

Dr. Antoine Hage

Cardiology
Cedars-Sinai Cardiac Amyloidosis
127 S San Vicente Blvd Ste A6100, 
Los Angeles,, CA 
Experienced in Catecholaminergic Polymorphic Ventricular Tachycardia
Cedars-Sinai Cardiac Amyloidosis
127 S San Vicente Blvd Ste A6100, 
Los Angeles,, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antoine Hage is a Cardiologist in Los Angeles,, California. Dr. Hage is rated as an Experienced provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Mitral Valve Regurgitation, Heart Failure, and Heart Transplant.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Cardiology
Licenses
Internal Medicine in CA
Hospital Affiliations
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Cedars-Sinai Cardiac Amyloidosis
127 S San Vicente Blvd Ste A6100, Los Angeles,, CA 90048
Other Locations
Cedars-Sinai California Heart Center
8670 Wilshire Blvd Fl 2, Beverly Hills,, CA 90211

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

9 Total Publications

Best Practices for Right Heart Catheterization in the Diagnosis of Pulmonary Hypertension.
Best Practices for Right Heart Catheterization in the Diagnosis of Pulmonary Hypertension.
Journal: Chest
Published: March 24, 2025
Similar Doctors
Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. John P. Mckenzie
Cardiac Electrophysiology | Cardiology
Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. John P. Mckenzie
Cardiac Electrophysiology | Cardiology

Eagle Rock Medlink Group Inc

4157 Eagle Rock Blvd, Suite 4, 
Los Angeles, CA 
 (9.7 miles away)
818-439-2021
Languages Spoken:
English
See accepted insurances

John Mckenzie is a Cardiac Electrophysiologist and a Cardiologist in Los Angeles, California. Dr. Mckenzie is rated as a Distinguished provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Ventricular Tachycardia, Catecholaminergic Polymorphic Ventricular Tachycardia, Arrhythmias, Pacemaker Implantation, and Cardiac Ablation.

Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. David Y. Mok
Cardiology
Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. David Y. Mok
Cardiology
201 South Buena Vista Street, Suite 100, 
Burbank, CA 
 (7.1 miles away)
818-848-6404
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Mok is a Cardiologist in Burbank, California. Dr. Mok is rated as a Distinguished provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Arrhythmias, Cardiomyopathy, Catecholaminergic Polymorphic Ventricular Tachycardia, Pacemaker Implantation, and Cardiac Ablation. Dr. Mok is currently accepting new patients.

Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Jason S. Bradfield
Cardiac Electrophysiology | Cardiology | Nuclear Medicine
Distinguished in Catecholaminergic Polymorphic Ventricular Tachycardia
Dr. Jason S. Bradfield
Cardiac Electrophysiology | Cardiology | Nuclear Medicine

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (3.8 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Bradfield is a Cardiac Electrophysiologist and a Cardiologist in Los Angeles, California. Dr. Bradfield is rated as an Elite provider by MediFind in the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. His top areas of expertise are Ventricular Tachycardia, Arrhythmias, Ectopic Heartbeat, Cardiac Ablation, and Pacemaker Implantation.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hage's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 46 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile